{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:44:32Z","timestamp":1767919472329,"version":"3.49.0"},"reference-count":23,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:00:00Z","timestamp":1586476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,4,4]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec id=\"s1\">\n                  <jats:title>Background\/Purpose<\/jats:title>\n                  <jats:p>To evaluate biomarkers as predictors of impending erosion progression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s2\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Variables were measured at baseline and annually up to 5\u00a0years in patients with recent-onset polyarthritis treated to zero swollen joints. Erosive status was defined as \u22655 Units in Sharp\/van der Heijde Erosion Score; Rapid Erosive Progression (REP) was defined\u00a0as an increase \u22655 Units in Erosion Scores between consecutive visits. Generalised estimating equations (GEEs) evaluated the effect on REP of positive anticyclic citrullinated peptides (ACPAs) and\/or rheumatoid factor (RF), C-reactive protein \u02c38.0 mg\/L (High-CRP) and 14-3-3\u03b7 protein \u22650.50\u00a0ng\/mL (High-14-3-3\u03b7), alone and in combinations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s3\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Out of 2155 evaluations in 749 consecutive patients, REP occurred after 186 (8.6%) visits, including 13 (2.2%) in patients recruited since 2010. Only 18\/537 (3.4%; 6\/411 (1.5%) in non-erosive vs 12\/126 (9.5%) in patients already erosive) visits without any positive biomarker were followed by REP; at least one biomarker was positive prior to REP in 168\/186 (90.3%) visits. Being positive for all four biomarkers conferred a positive predictive value (PPV) of 30.0% (RR 21.8) in patients non-erosive at the visit versus 35.5% (RR 3.07) in those already erosive. High-14-3-3\u03b7 increased REP only in visits with High-CRP (eg, RR 2.5 to 3.9 when ACPA also positive) and in patients with non-erosive status (eg, RR from 4.3 to 9.4 when also High-CRP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s4\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Adding High-14-3-3\u03b7 to positive antibodies and CRP improves prediction of impending REP. Although REP is becoming rarer, signatures of biomarkers might help to adapt treatment strategies in at-risk individuals, even those already erosive.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2020-001191","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T10:45:14Z","timestamp":1588675514000},"page":"e001191","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Impending radiographic erosive progression over the following year in a cohort of consecutive patients with inflammatory polyarthritis: prediction by serum biomarkers"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct00512239","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00512239","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nathalie","family":"Carrier","sequence":"first","affiliation":[{"name":"Centre int\u00e9gr\u00e9 universitaire de sant\u00e9 et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSSE-CHUS), Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur J","family":"de Brum-Fernandes","sequence":"additional","affiliation":[{"name":"Centre int\u00e9gr\u00e9 universitaire de sant\u00e9 et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSSE-CHUS), Quebec, Canada"},{"name":"Universit\u00e9 de Sherbrooke, Sherbrooke, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Liang","sequence":"additional","affiliation":[{"name":"Centre int\u00e9gr\u00e9 universitaire de sant\u00e9 et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSSE-CHUS), Quebec, Canada"},{"name":"Universit\u00e9 de Sherbrooke, Sherbrooke, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Masetto","sequence":"additional","affiliation":[{"name":"Centre int\u00e9gr\u00e9 universitaire de sant\u00e9 et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSSE-CHUS), Quebec, Canada"},{"name":"Universit\u00e9 de Sherbrooke, Sherbrooke, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Roux","sequence":"additional","affiliation":[{"name":"Centre int\u00e9gr\u00e9 universitaire de sant\u00e9 et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSSE-CHUS), Quebec, Canada"},{"name":"Universit\u00e9 de Sherbrooke, Sherbrooke, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norma K","family":"Biln","sequence":"additional","affiliation":[{"name":"Augurex Life Sciences Corp, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter P","family":"Maksymowych","sequence":"additional","affiliation":[{"name":"University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-5821","authenticated-orcid":false,"given":"Gilles","family":"Boire","sequence":"additional","affiliation":[{"name":"Centre int\u00e9gr\u00e9 universitaire de sant\u00e9 et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSSE-CHUS), Quebec, Canada"},{"name":"Universit\u00e9 de Sherbrooke, Sherbrooke, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"2025090313312424000_6.1.e001191.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2025090313312424000_6.1.e001191.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110207"},{"key":"2025090313312424000_6.1.e001191.3","first-page":"234","article-title":"Anti-CCP: a truly helpful rheumatoid arthritis test?","volume":"62","author":"Braschi","year":"2016","journal-title":"Can Fam Physician"},{"key":"2025090313312424000_6.1.e001191.4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131446"},{"key":"2025090313312424000_6.1.e001191.5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13075-015-0799-7","article-title":"Serum 14-3-3\u03b7 level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab","volume":"17","author":"Hirata","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025090313312424000_6.1.e001191.6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13075-016-0935-z","article-title":"Serum levels of 14-3-3\u03b7 protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis","volume":"18","author":"Carrier","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090313312424000_6.1.e001191.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep155"},{"key":"2025090313312424000_6.1.e001191.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.121160"},{"key":"2025090313312424000_6.1.e001191.9","doi-asserted-by":"crossref","DOI":"10.1186\/ar4092","article-title":"Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort","volume":"14","author":"Fautrel","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2025090313312424000_6.1.e001191.10","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000245","article-title":"Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data","volume":"2","author":"Granger","year":"2016","journal-title":"RMD Open"},{"key":"2025090313312424000_6.1.e001191.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.24353"},{"key":"2025090313312424000_6.1.e001191.12","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/acr.20288","article-title":"Outcomes in recent-onset inflammatory polyarthritis differ according to initial titers, persistence over time, and specificity of the autoantibodies","volume":"62","author":"Guzian","year":"2010","journal-title":"Arthritis Care Res(Hoboken)"},{"key":"2025090313312424000_6.1.e001191.13","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/acr.21923","article-title":"Predictors of pain for patients with early inflammatory polyarthritis","volume":"65","author":"Dobkin","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313312424000_6.1.e001191.14","unstructured":"Fries J , Hunder G , Bloch D , et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: summary. Appendix I. Criteria for the classification and diagnosis of the rheumatic diseases . Atlanta: Arthritis Foundation: Primer on the rheumatic diseases 11th, 1997: 559\u201361."},{"key":"2025090313312424000_6.1.e001191.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040226"},{"key":"2025090313312424000_6.1.e001191.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.009"},{"key":"2025090313312424000_6.1.e001191.17","first-page":"261","article-title":"How to read radiographs according to the sharp\/van der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"2025090313312424000_6.1.e001191.18","first-page":"2306","article-title":"Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence","volume":"29","author":"Bruynesteyn","year":"2002","journal-title":"J Rheumatol"},{"key":"2025090313312424000_6.1.e001191.19","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313312424000_6.1.e001191.20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B (Methodological)"},{"key":"2025090313312424000_6.1.e001191.21","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.202"},{"key":"2025090313312424000_6.1.e001191.22","doi-asserted-by":"crossref","DOI":"10.1186\/ar4547","article-title":"14-3-3\u03b7 is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage","volume":"16","author":"Maksymowych","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2025090313312424000_6.1.e001191.23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13075-020-2110-9","article-title":"Tumour necrosis factor alpha promotes secretion of 14-3-3\u03b7 by inducing necroptosis in macrophages","volume":"22","author":"Trimova","year":"2020","journal-title":"Arthritis Res Ther"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:31:34Z","timestamp":1756931494000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,5,5]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/rmdopen-2020-001191"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001191","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}